Oral delivery of salmon calcitonin

被引:99
作者
Lee, YH [1 ]
Sinko, PJ [1 ]
机构
[1] Rutgers State Univ, Coll Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA
关键词
salmon calcitonin; permeability; oral absorption; bioavailability;
D O I
10.1016/S0169-409X(00)00063-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Calcitonin plays a crucial role in both calcium homeostasis and bone remodeling, Establishing an oral delivery system for CT is of great importance since CT is currently administered only parenterally or nasally. Poor absorption and rapid proteolytic degradation have impeded the clinical development of an orally administered sCT drug product. Potential approaches to enhance sCT absorption include the use of formulation additives in the drug product to transiently modulate the intestinal environment ol targeting specific intestinal regions that may have favorable peptide delivery properties (e.g., low residual volume, high absorptive surface area or reduced enzymatic activity). Potential approaches to limit the activity of intestinal enzymes include adjusting the pH of the intestinal contents to the pH minima of specific enzymes or maintaining high local drug concentrations in order to saturate enzyme systems. In this review, pharmacokinetic studies elucidating the rate-limiting steps fur achieving adequate sCT oral bioavailability are detailed, Further, several approaches for enhancing the oral absorption of sCT are presented. Specific emphasis is placed on regio-specific targeting (e.g., intestinal regional differences in dilution and spreading, etc.) and modulation of the intestinal environment (e.g., changing pH, etc.). The approaches are evaluated in in vitro and in vivo models. Finally, this paper closes with a brief section of concluding remarks. (C) 2000 Published by Elsevier Science B.V.
引用
收藏
页码:225 / 238
页数:14
相关论文
共 59 条
[31]  
MACKAY M, 1991, BIOTECHNOL GENET ENG, V8, P251
[32]   THE ROLE OF CALCITONIN IN THE DEVELOPMENT AND TREATMENT OF OSTEOPOROSIS [J].
MCDERMOTT, MT ;
KIDD, GS .
ENDOCRINE REVIEWS, 1987, 8 (04) :377-390
[33]  
MOORE PL, 1986, J HYPERTENS, V4, pS186
[34]   THE COLON AS A SITE FOR DRUG DELIVERY [J].
MRSNY, RJ .
JOURNAL OF CONTROLLED RELEASE, 1992, 22 (01) :15-34
[35]   Delivery system design for improvement of intestinal absorption of peptide drugs [J].
Muranishi, S .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1997, 117 (07) :394-414
[36]  
Nakamuta H, 1997, J CLIN LAB ANAL, V11, P129, DOI 10.1002/(SICI)1098-2825(1997)11:3<129::AID-JCLA2>3.0.CO
[37]  
2-5
[38]  
NEUSCH E, 1980, CALCITONIN, P352
[39]  
PAGANI G, 1991, INT J CLIN PHARM TH, V29, P329
[40]   DRUGS USED IN THE TREATMENT OF METABOLIC BONE-DISEASE - CLINICAL-PHARMACOLOGY AND THERAPEUTIC USE [J].
PATEL, S ;
LYONS, AR ;
HOSKING, DJ .
DRUGS, 1993, 46 (04) :594-617